Combination of Activating Blood Circulation and Detoxifying Chinese Medicines Played an Anti-Inflammatory Role in Unstable Angina Patients after Percutaneous Coronary Intervention: A Multicenter, Open-Labeled, Randomized Controlled Trial
| Autor: | Xiao-juan Ma, Wen-hui Duan, Ying Zhang, Jie Gao, Dazhuo Shi, Baoyi Guan, Ke-ji Chen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
China food.ingredient medicine.medical_treatment Anti-Inflammatory Agents Traditional Chinese medicine Blood stasis Gastroenterology law.invention Angina Pectoris Angina food Percutaneous Coronary Intervention Randomized controlled trial law Internal medicine medicine Humans Pharmacology (medical) Angina Unstable Unstable angina business.industry Percutaneous coronary intervention General Medicine medicine.disease Andrographis Complementary and alternative medicine Pill business Drugs Chinese Herbal |
| Zdroj: | Chinese journal of integrative medicine. 27(11) |
| ISSN: | 1672-0415 |
| Popis: | To investigate the combined anti-inflammatory effect of activating blood circulation and detoxifying Chinese medicines in unstable angina (UA) patients. This study was an open-labeled, randomized controlled trial conducted in 5 centers in Beijing. A total of 154 patients were randomized into two groups at a 1:1 ratio by random numbers. Based on the conventional treatment, patients in the activating blood circulation (ABC) group were treated with Guanxin Danshen Droping Pill (冠心丹参滴丸, 0.4 g, thrice daily), and patients in the activating blood circulation and detoxifying (ABCD) group were treated with Guanxin Danshen Droping Pill (0.4 g, thrice daily) and Andrographis tablet (0.2 g, thrice daily) for 4 weeks. The primary outcome was the serum level of high sensitive C reaction protein (hs-CRP), and the secondary outcome index included the serum levels of tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), soluble CD40 ligand (sCD40L), thrombomodulin (TM), the score of angina pectoris, the score of blood stasis syndrome, and the score of Chinese medicine symptoms, observed at week 0 and week 4. A total of 144 patients completed the trial (ABC group, n=70; ABCD group, n=74). There were no significant differences in the clinical baseline characteristics between the two groups. When compared with the ABC group, ABCD group showed better performance in reducing the level of inflammatory factors, especially hs-CRP (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink